Abstract
Introduction: Urachal carcinoma is characterized by high malignancy, poor prognosis, and late stage of diagnosis. There is a lack of unanimous clinical treatment guidelines. We summarize the characteristics, treatment, and outcomes of urachal carcinoma from our center, hoping to provide a reference for diagnosis and treatment. Methods: We retrospectively analyzed the clinical data of 21 patients with urachal carcinoma who were treated at our center from January 2010 to August 2022, and all patients were followed up. Results: The average survival time was 67.1 ± 9.1 (ranging from 49.3 to 84.9) months. The average relapse-free survival was 48.8 ± 9.9 (ranging from 29.5 to 68.2) months. Six patients received adjuvant therapy, mainly chemotherapy. Five patients died during follow-up. Conclusions: Early physical examination may be helpful for early detection of urachal carcinoma. Surgical treatment is still preferred for localized urachal carcinoma. Lymph node dissection may facilitate accurate staging, and positive margin usually results in a worse prognosis. Adjuvant therapy, mainly chemotherapy, may help improve the prognosis. The application of radiotherapy, targeted therapy, and immunotherapy still needs further exploration.
Journal Section:
Research Article
References
1.
Begg
RC
. The urachus: its anatomy, histology and development
. J Anat
. 1930
;64
(Pt 2
):170
–83
.2.
Johnson
DE
, Hodge
GB
, Abdul-Karim
FW
, Ayala
AG
. Urachal carcinoma
. Urology
. 1985
;26
(3
):218
–21
. 3.
Sheldon
CA
, Clayman
RV
, Gonzalez
R
, Williams
RD
, Fraley
EE
. Malignant urachal lesions
. J Urol
. 1984
;131
(1
):1
–8
. 4.
Szarvas
T
, Módos
O
, Niedworok
C
, Reis
H
, Szendröi
A
, Szász
MA
, et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases
. Urol Oncol
. 2016
;34
(9
):388
–98
. 5.
Hamilou
Z
, North
S
, Canil
C
, Wood
L
, Hotte
S
, Sridhar
SS
, et al. Management of urachal cancer: a consensus statement by the Canadian urological association and genitourinary medical oncologists of Canada
. Can Urol Assoc J
. 2020
;14
(3
):E57
–64
. 6.
Duan
F
, Zhai
W
, Zhang
B
, Guo
S
. Urachal carcinoma: impact of recurrence pattern and lymphadenectomy on long-term outcomes
. Cancer Med
. 2020
;9
(12
):4166
–74
. 7.
Henly
DR
, Farrow
GM
, Zincke
H
. Urachal cancer: role of conservative surgery
. Urology
. 1993
;42
(6
):635
–9
. 8.
Ashley
RA
, Inman
BA
, Sebo
TJ
, Leibovich
BC
, Blute
ML
, Kwon
ED
, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy
. Cancer
. 2006
;107
(4
):712
–20
. 9.
Bruins
HM
, Visser
O
, Ploeg
M
, Hulsbergen-van de Kaa
CA
, Kiemeney
LA
, Witjes
JA
. The clinical epidemiology of urachal carcinoma: results of a large, population based study
. J Urol
. 2012
;188
(4
):1102
–7
. 10.
Siefker-Radtke
A
. Urachal adenocarcinoma: a clinician's guide for treatment
. Semin Oncol
. 2012
;39
(5
):619
–24
. 11.
Liu
Z
, Yu
X
, Hu
J
, Li
F
, Wang
S
. Umbilicus-sparing laparoscopic versus open approach for treating symptomatic urachal remnants in adults
. Medicine
. 2018
;97
(26
):e11043
. 12.
Ortiz
SL
, Alonso Prieto
MA
, Campanario Pérez
F
, Alvarez-Silva
I
, De Cabo Ripoll
M
, García Díez
F
. Treatment of urachal disorders: the open and laparoscopic surgery approach
. Arch Esp Urol
. 2017
;70
(3
):357
–60
.13.
Madeb
R
, Knopf
JK
, Nicholson
C
, Donahue
LA
, Adcock
B
, Dever
D
, et al. The use of robotically assisted surgery for treating urachal anomalies
. BJU Int
. 2006
;98
(4
):838
–42
. 14.
Stokkel
LE
, van de Kamp
MW
, Schaake
EE
, Boellaard
TN
, Hendricksen
K
, van Rhijn
BWG
, et al. Robot-assisted partial cystectomy versus open partial cystectomy for patients with urachal cancer
. Urol Int
. 2022
;106
(8
):840
–7
. 15.
Niedworok
C
, Panitz
M
, Szarvas
T
, Reis
H
, Reis
AC
, Szendröi
A
, et al. Urachal carcinoma of the bladder: impact of clinical and immunohistochemical parameters on prognosis
. J Urol
. 2016
;195
(6
):1690
–6
. 16.
Herr
HW
, Bochner
BH
, Sharp
D
, Dalbagni
G
, Reuter
VE
. Urachal carcinoma: contemporary surgical outcomes
. J Urol
. 2007
;178
(1
):74
–8
; discussion 8. 17.
Jia
Z
, Chang
X
, Li
X
, Wang
B
, Zhang
X
. Urachal carcinoma: are lymphadenectomy and umbilectomy necessary
. Med Sci Monit
. 2020
;26
:e927913
. 18.
Molina
JR
, Quevedo
JF
, Furth
AF
, Richardson
RL
, Zincke
H
, Burch
PA
. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases
. Cancer
. 2007
;110
(11
):2434
–40
. 19.
Siefker-Radtke
AO
, Gee
J
, Shen
Y
, Wen
S
, Daliani
D
, Millikan
RE
, et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience
. J Urol
. 2003
;169
(4
):1295
–8
. 20.
Pinthus
JH
, Haddad
R
, Trachtenberg
J
, Holowaty
E
, Bowler
J
, Herzenberg
AM
, et al. Population based survival data on urachal tumors
. J Urol
. 2006
;175
(6
):2042
–7
; discussion 7. 21.
Mylonas
KS
, P
OM
, Ziogas
IA
, El-Kabab
L
, Nasioudis
D
. Malignant urachal neoplasms: a population-based study and systematic review of literature
. Urol Oncol
. 2017
;35
(1
):33.e11
–9
. 22.
Jung
Hyun Ae
, Sun
Jong-Mu
, Park
Se Hoon
, Kwon
Ghee Young
, Lim
Ho Yeong
. Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer
. Chemotherapy
. 2014
;60
(2
):73
–80
. 23.
Chen
M
, Xue
C
, Huang
RQ
, Ni
MQ
, Li
L
, Li
HF
, et al. Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant urachal tumor
. Front Oncol
. 2021
;11
:739134
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
